GlassScriptPhysician profile
Daniel A Delvecchio
NPI 1447372511
$140,678.33
in general payments reported to CMS, 2019-2025
10 companies · $19K in 2025
The $19K reported for 2025 was more than what 97% of Plastic Surgery providers received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $7,922 · 2021: $27K · 2022: $26K · 2023: $22K · 2024: $25K · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $65K · Food and Beverage: $845.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $65,330.44 |
| Food and Beverage | $844.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Microaire Surgical Instruments LLC | $138,716.40 | 2019-2025 | Pal |
| Davol INC. | $556.66 | 2023 | Phasix Mesh |
| Tepha INC | $303.93 | 2019-2020 | |
| Sientra, INC. | $288.55 | 2019-2022 | |
| Bard Peripheral Vascular, INC. | $224.05 | 2021 | |
| Becton, Dickinson and Company | $153.29 | 2024 | |
| Galderma Laboratories, L.P. | $150.00 | 2021 | |
| Abbvie INC. | $135.00 | 2024 | |
| Allergan, INC. | $121.94 | 2019 | |
| Endo Pharmaceuticals INC. | $28.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Delvecchio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.